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COMMENTARY
Report from the 2nd Cardiovascular 
Outcome Trial (CVOT) Summit of the Diabetes 
and Cardiovascular Disease (D&CVD) EASD 
Study Group
Oliver Schnell1*, Eberhard Standl1, Doina Catrinoiu2, Stefano Genovese3, Nebojsa Lalic4, Jan Skra5, Paul Valensi6, 
Dario Rahelic7 and Antonio Ceriello3
Abstract 
The 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD 
Study Group was held on the 20th–21st October 2016 in Munich. This second Summit was organized in light of 
recently published CVOTs on diabetes, with the aim of serving as a reference meeting for discussion on this topic. 
Along with presentations on the results of the most recently published CVOTs, panel discussions on trial implications 
for reimbursement and the perspective of cardiologists and/or nephrologists, as well as on CVOTs weaknesses and 
potentials constituted the heart of the program. Future activities of the D&CVD EASD Study Group in 2017 include an 
annual meeting in Milano and the 3rd CVOT Summit on Diabetes of the D&CVD EASD Study Group, in Munich (http://
www.dcvd.org).
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Background
Since the 2008 FDA Guidance for industry “Diabetes 
Mellitus: Evaluating Cardiovascular Risk in New Anti-
diabetic Therapies in Type 2 Diabetes” [1] sponsors of all 
new antihyperglycemic drugs should demonstrate that 
the therapy will not result in an unacceptable increase 
in CV risk. Among the evaluated endpoints stand car-
diovascular mortality, myocardial infarction and stroke, 
but also can include hospitalization for acute coronary 
syndrome, urgent revascularization procedures, and 
possibly other endpoints. Moreover, the FDA favors the 
enrollment of high-risk patients, such as those with rela-
tively advanced disease, elderly patients, or under some 
degree of renal impairment. Along the lines of the FDA, 
the European Medicines Agency (EMA) [2] also requires 
an overall assessment of safety to exclude that a new drug 
increases the risk of macrovascular complications such as 
CVD.
Main body
The 2nd CVOT Summit on Diabetes of the D&CVD 
EASD Study Group had the goal to present and discuss 
the results and implications from the most recently com-
pleted CVOTs (see summary Tables 1, 2).  
Key topics and aims of the 2nd CVOT Summit on Dia-
betes were:
1. Discuss on implications of SGLT-2 inhibitors and 
CVOT results on renal outcomes.
 Glycemic control was highlighted as a key strategy 
for renal protection since it reduces the risk of albu-
minuria and dialysis. By preventing hyperfiltration, 
SGLT-2 inhibitors like empagliflozin reduce intraglo-
merular pressure, and in addition to standard care, 
can reduce the risk of progression of CKD. Other 
potential explanations for the beneficial cardiovas-
cular and renal effects of SGLT-2 inhibitors might 
be by improving oxygen delivery and/or provid-
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ing hydroxybutyrate as heart fuel, but potentially 
also through an increase in glucagon. In summary, 
SGLT-2 inhibitors have the potential to be as revolu-
tionary a therapy as RAAS inhibition.
2. Summarize the key learnings from recent CVOTs 
(namely, EMPA-REG, LEADER & SUSTAIN-6), 
especially with respect to heart failure (HF).
 Diabetes markedly increases the risk for HF even 
at a young age. Furthermore, HF in diabetes has a 
poor prognosis, with up to 10 times increased mor-
tality in comparison with patients with diabetes but 
without HF. Even though strict glycemic control 
has not shown a reduction of HF events, results of 
recent CVOTs have shown that certain antihyper-
glycemic therapy can, independently of glycemic 
control, lead to a decrease of HF risk. However, evi-
dence for high rates of undiagnosed HF in recent 
CVOTs calls for further attention into HF charac-
terization in the context of CVOTs and/or antidia-
betic treatments [3]. On the other hand, the anal-
ysis of the results on HF observed for these latest 
trials call for further research into the possible bio-
logical mechanisms (such as the role of cardiac fuel 
overload (lipo-gluco-toxicity) vs renal glucotoxic-
ity; or the potential association with hypoglycemia) 
leading to them.
3. Present an update on lipid studies, and reflect on 
their influence on diabetes and CVOT design and 
results.
 On the topic of lipid therapy in the context of dia-
betes, apart from the need for a risk-based LDL-
cholesterol/non-LDL-cholesterol goal determina-
tion, treatment recommendations include statins 
as first line approach, to be possibly complemented 
with ezetimibe or PCSK9 inhibitors, fibrates/
omega-3 fatty acids in selected patients. Further-
more, to combat hypertriglyceridemia, life style 
modification/glucose control are highly recom-
mendable.
4. Include the perspectives of other health professionals 
like cardiologists in the discussion of future implica-
tions of CVOTs.
 One of the general points of agreement between 
diabetologists and cardiologists was the importance 
of improving on study design. Issues related to end-
point selection and under-powering, short study 
duration and lack of head-to-head comparisons were 
highlighted. Reconsideration of end-points, study 
population selection criteria, comparator selection 
and statistical analysis were among the suggestions 
derived from the discussion to improve on CVOT 
results.
5. Promote discussion on the results and implications 
of CVOTs for therapy and reimbursement.
 Despite the potential of CVOT results to affect treat-
ment guidelines and reimbursement plans in Europe, 
so far in Germany, for instance, CVOT results have 
not affected much drug pricing. Partly due to the dif-
ferent “standard of care according to local guidelines”, 
which may lead to insufficient glycemic control (and 
antihypertensive treatment). But also to the insuf-
ficiently individually defined treatment escalation 
and treatment goals pre-randomization and the lack 
of comprehensive analyses on regional influences, 
which hamper the use of CVOT results as regulatory 
evidence.
6. Enforce cross-sectorial communication among the 
scientific community, trial sponsors and regulatory 
and reimbursement authorities.
Other questions debated during the 2nd CVOT Sum-
mit on Diabetes were the following:
Table 1 Overview of basic characteristics of CVOTs terminated in 2015 and published in 2016










EMPA‑REG Completed Empagliflozin SGLT‑2 inhibi‑
tor
Empagliflozin 
10 mg versus 
empagliflozin 
25 mg versus 
placebo
CV death, MI, or 
stroke
7000 3.1 07.2010 to 
04.2015
NCT01131676
LEADER Completed Liraglutide GLP‑1 inhibitor Liraglutide versus 
placebo
CV death, MI, or 
stroke
9340 3.8 08.2010 to 
12.2015
NCT01179048
SUSTAIN‑6 Completed Semaglutide GLP‑1 inhibitor Semaglutide 0.5 mg 
versus semaglu‑
tide 1.0 mg versus 
placebo
CV death, MI, or 
stroke
3299 1.99 02.2013 to 
01.2016
NCT01720446
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1. What are the key learnings from CVOTs in 2016?
 One of the main points of discussion. In general 
it was agreed that the latest CVOTs have shown 
that glucose lowering drugs can decrease CV mor-
bidity and mortality. However, the exact mecha-
nisms involved are still unknown. To which extent 
is it due to glucose-lowering mechanisms or by 
means of non-glycemic effects like weight loss or 
blood pressure control, remains under question. 
The positive cardiovascular effects observed in 
this year’s published trials on GLP-1 RA, LEADER 
and SUSTAIN-6, demonstrated clear within-class 
differences, especially when compared to results 
observed in trials like ELIXA. This variability of 
results observed for drugs from the same class 
(GLP-1 RA) raises questions as to whether it is rea-
sonable to expect a class effect for anti-hyperglyce-
mic drugs. Moreover, the dissimilarities between 
trials with respect to single cardiovascular end-
points raises the point of mechanistic differences 
between GLP-1 RA and SGLT-2 inhibitors. While 
effects driven by GLP-1 RA would be mainly medi-
ated by endothelial changes leading to improved 
myocardial perfusion, SGLT-2 inhibitors would 
exert their action by mediating hemodynamic 
changes.
 For all the above, it is necessary therefore to deepen 
the knowledge on the mechanism of action of these 
drugs, and to that effect initiate new trials aiming 
on that direction.
2. Can CVOTs lead to changes in treatment algo-
rithms?
 The general answer to this question was affirma-
tive under a certain set of conditions, namely that 
results are consistent among trials with the same 
drug and therefore there is an independent confir-
mation of results. Furthermore, trial design must 
be of such quality that allows results validation 
(pre-specified statistical analysis plan, P < 0.01 for 
primary endpoint and consistent results in major 
subgroups…). Finally, drugs examined by CVOTs 
must show a certain strength of demonstrated ben-
efits and/or safety signals to be considered in the 
guideline recommendations by professional asso-
ciations.
3. Can CVOT results be extrapolated to broader pop-
ulations?
 In general, it seems reasonable to assume CV safety 
in broader populations given the high risk profile 
of the studied groups, even when this very same 
condition, the inclusion of high risk populations 
in CVOT design, might be a limiting factor for 
extrapolation. However, result extrapolation might 
be possible to some extent provided that specific 
eligibility criteria of target populations are satisfied 
and that subgroup analysis of CVOT subjects show 
consistency of results.
Conclusion
 The 2nd Meeting on CVOTs in Diabetes of the D&CVD 
EASD Study Group was a successful scientific meeting 
where results from the most recently completed trials 
were discussed in a cross-functional international set-
ting. The Summit discussed on the learnings and limi-
tations of current CVOT study design. Their impact on 
treatment guidelines and reimbursement and viewed 
CVOTs results needs to be considered under the special-
ized perspectives of the nephrologist, cardiologist and 
diabetologist.
Scientific activities of the D&CVD EASD Study Group 
in 2017 include the annual meeting in Milano and the 3rd 
CVOT Summit on Diabetes of the D&CVD EASD Study 
Group, in Munich (http://www.dcvd.org).
Abbreviations
CKD: chronic kidney disease; CVD: cardiovascular disease; CVOT: Cardiovascu‑
lar Outcome Trial; D&CVD: Diabetes and Cardiovascular Disease; EASD: Euro‑
pean Association for the Study of Diabetes; EMA: European Medicine Agency; 
FDA: Food and Drug Administration; GLP‑1: glucagon‑like‑peptide 1; HF: heart 
failure; MI: myocardial infarct; SGLT: 2‑sodium glucose linked transporter 2.
Authors’ contributions
All authors contributed to the discussion and content of the report and 
agreed to its publication. All authors read and approved the final manuscript.
Author details
1 Forschergruppe Diabetes e.V., Munich, Ingolstaedter Landstrasse 1, 
85764 Neuherberg, Germany. 2 Internal Medicine Department, Clinical 
County Emergency Hospital Constanta, Tomis Blvd, No. 145, 900591 Con‑
stanta, Romania. 3 Diabetes and Metabolic Disease Unit, IRCCS MultiMedica, 
Via Milanese 300, 20099 Sesto San Giovanni, MI, Italy. 4 Clinic for Endocri‑
nology, Diabetes and Metabolic Diseases, Clinical Center of Serbia, Faculty 
of Medicine, University of Belgrade, Dr Subotica 13, Belgrade 11000, Serbia. 
5 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles 
University, U Nemocnice 1, 128 08 Prague 2, Czech Republic. 6 Department 
of Endocrinology Diabetology Nutrition, CINFO, CRNH‑IdF, Jean VERDIER Hos‑
pital, Paris 13 University, Avenue du 14 Juillet, 93140 Bondy, France. 7 Diabetes 
and Metabolic Disorders, Dubrava University Hospital, Avenija Gojka Šuška 6, 
10000 Zagreb, Croatia. 
Acknowledgements
We would like to thank all speakers and participants on the 2nd CVOT Summit 
for their active involvement in the scientific discussions leading to the present 
report. Moreover, we would like to acknowledge the industry partners for their 
support of the meeting.
Competing interests
The authors declare that they have no competing interests
Availability of data and materials
Data is derived from the discussions during the 2nd CVOT Summit.
Received: 30 January 2017   Accepted: 3 February 2017
Page 5 of 5Schnell et al. Cardiovasc Diabetol  (2017) 16:35 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
References
 1. Federal Drug Administration (FDA). Guidance for industry diabetes 
mellitus—evaluating cardiovascular risk in new antidiabetic therapies 
to treat type 2 diabetes. 2008. http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. 
Accessed 20 Dec 2016.
 2. European Medicines Agency (EMA). Guideline on clinical investigation of 
medicinal products in the treatment or prevention of diabetes mellitus. 
Verfügbar unter. http://www.ema.europa.eu/docs/en_GB/document_
library/Scientific_guideline/2012/06/WC500129256.pdf (2012). Accessed 
10 Jan 2016.
 3. Standl E, Schnell O, McGuire DK. Heart failure considerations of antihyper‑
glycemic medications for type 2 diabetes. Circ Res. 2016;118(11):1830–43.
 4. Zannad F, et al. Heart failure and mortality outcomes in patients with type 
2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, 
randomised, double‑blind trial. Lancet. 2015;385(9982):2067–76.
 5. Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in 
type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.
 6. Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabe‑
tes. N Engl J Med. 2016;375(4):311–22.
 7. Marso SP, et al. Semaglutide and cardiovascular outcomes in patients 
with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.
